United Therapeutics Corporation or Corcept Therapeutics Incorporated: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. United Therapeutics Corporation and Corcept Therapeutics Incorporated, two prominent players in the industry, have shown contrasting approaches over the past decade.

From 2014 to 2023, United Therapeutics consistently reported higher SG&A expenses, peaking at approximately 487 million in 2022. This represents a steady increase of around 28% from their 2014 figures. In contrast, Corcept Therapeutics, while starting with significantly lower expenses, saw a dramatic rise of over 400% during the same period, reaching nearly 184 million in 2023.

This data highlights the strategic differences in cost management between the two companies. While United Therapeutics maintains a higher baseline, Corcept's rapid increase suggests aggressive expansion or investment in administrative capabilities. Understanding these trends is essential for investors and stakeholders aiming to gauge the financial health and strategic direction of these biotech firms.